tecfidera
aducanumab rais pt
beat top bottom line guidanc
main focu remain tecfidera ipr decis expect feb
aducanumab expect bla submiss adjust
model reflect manag commentari aducanumab margin
consider rais pt
updat aducanumab model reflect manag color
margin learn al sandrock compani
price aducanumab fair margin well econom
aducanumab file earli rais price aducanumab
per patient per year in-lin brand alzheim diseas
drug provigil nuvigil rang price
account manag color around margin
go tecfidera ipr next week assum neg outcom
gener enter dcf could neg
impact probability-adjust tecfidera await final
decis next week ahead ipr decis previous spoke
patent kol gave probabl success assum
tecfidera goe gener lose ipr dcf could
neg impact need get clariti around market
dynam vumer recent launch also updat vumer
ramp reflect initi inventori record
beat guidanc report vs
con ep consensu ms sale slightli
consensu tecfidera interferon miss vs
con tysabri revenu vs con share
rituxan co-promot beat vs spinraza
slightli vs con us busi beat vs
row vs provid revenu guidanc
revenu howev note
manag assum gener entri part guidanc
non-gaap ep rang guidanc sg
tax rate
tr target
guidanc consensu could assum flat us sale ms
spinraza rituxan biosimilar impact assumpt eu sale avonex tysabri declin
base increas volum decreas price note slide ms inventori channel
increas question whether expect inventori drawn
draw zolgensma gene therapi impact sma type infant rituxan biosimilar
impact co-promot revenu compani suggest resili ms base busi
await tecfidera decis earli februari earli year highlight maxim
resili core ms busi on-going invest earli stage asset vumer launch
well continu biosimilar anti-tnf growth
catalyst tecfidera ipr decis feb aducanumab regulatori file
page
figur million dollar except per share data
incom statement million
other biosimilar
ad sale adjust
amort intang non-
profit attrib non-control interest
amort acquir intang
strh research compani report updat
page
figur million dollar except per share data
balanc sheet million
collater loan secur
current portion note payabl
strh research compani report updat
page
figur million dollar except per share data
statement
adjust non-oper item
chang
proce sale manufactur facil
proce sale matur market secur
purchas market secur
conting consider fumapharm
chang invest
chang
strh research compani report updat
page
figur million dollar except per share data
million except per share data
chang work capit
-mileston payment tecfidera
present valu flow
premium wacc
npv
npv termin valu
tv npv
valu samsung stake
share outstand million
compani report strh estim
strh research compani report updat
page
inc biopharmaceut compani engag discov develop deliv
therapi neurolog neurodegen diseas offer tecfidera avonex plegridi
tysarbi zinbryta fampyra treatment multipl sclerosi spinraza treatment
spinal muscular atrophi fumaderm treatment sever plaqu psoriasi compani
found charl weissmann heinz schaller kenneth murray walter gilbert phillip allen
sharp headquart cambridg
surpris announc fda aducanumab phase data thesi hing
aducanumab obtain fda approv pipelin tauopathi al part
earli give credit pipelin ad wait data biogen
grow biosimilar pipelin expans china market samsung bioepi
collabor think street underappreci abil grow anoth segment beyond ms
spinraza sma rate buy pt
valuat risk
price target deriv dcf assum ms sale declin
spinraza peak sale adjust ad sale model
dcf termin growth rate discount rate instead matur
biotech compani account potenti commerci execut ad termin valu
arriv pt
risk rate price target includ on-going fda reject aducanumab bla file ad
competit sma lose tecfidera ipr pipelin visibl
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
